| Identification | Back Directory | [Name]
2-Anthracenecarboxamide, 9,10-dihydro-N-[4-[(4-methylphenyl)amino]-6-quinazolinyl]-9,10-dioxo-4,5-bis(phenylmethoxy)- | [CAS]
2393787-80-7 | [Synonyms]
2-Anthracenecarboxamide, 9,10-dihydro-N-[4-[(4-methylphenyl)amino]-6-quinazolinyl]-9,10-dioxo-4,5-bis(phenylmethoxy)- | [Molecular Formula]
C44H32N4O5 | [MOL File]
2393787-80-7.mol | [Molecular Weight]
696.75 |
| Chemical Properties | Back Directory | [Boiling point ]
870.4±65.0 °C(predicted) | [density ]
1.365±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
11.38±0.20(predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of GLUT1 and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research[1]. | [in vivo]
GLUT1/EGFR-IN-1 (compound H) (4-8 mg/kg, IP, for two weeks) inhibits the growth of the MDA-MB231-transplanted tumour cells in a nude mice model[1]. | Animal Model: | BALB/c-neu female mice (Four- to five-week-old, n=5)[1] | | Dosage: | 4, 8 mg/kg | | Administration: | IP, for two weeks | | Result: | Inhibited the growth of the MDA-MB231 transplanted tumour model in nude mice. |
| [IC 50]
GLUT1; EGFR | [References]
[1] Wang C, et al. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma. Eur J Pharm Sci. 2024 Jul 1;198:106789. DOI:10.1016/j.ejps.2024.106789 |
|
|